The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease
about
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewBedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment CriteriaOrgan-specific responses to circulatory disturbances in heart failure: new insightsHeart failure in patients with chronic kidney disease: a systematic integrative reviewStatins in heart failure: do we need another trial?Cardiorenal syndrome: a cardiologist's perspective of pathophysiologyBurden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature ReviewCardiac assessment for renal transplantationStatins in the treatment of chronic heart failure: a systematic reviewImproved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trialBaseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry)Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.Increased mortality among survivors of myocardial infarction with kidney dysfunction: the contribution of gaps in the use of guideline-based therapies.Diminished renal function and the incidence of heart failure.Cardiovascular complications of diabetic kidney disease.Reduction of Na/K-ATPase affects cardiac remodeling and increases c-kit cell abundance in partial nephrectomized mice.Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure.Epidemiology of chronic kidney disease in heart failure.Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort studyEffectiveness of β-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease.Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations.Acute and acute-on-chronic kidney injury of patients with decompensated heart failure: impact on outcomes.Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database.Heart failure in subjects with chronic kidney disease: Best management practices.Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease.Patterns of care quality and prognosis among hospitalized ischemic stroke patients with chronic kidney disease.Role of Pulsatile Hemodynamics in Acute Heart Failure: Implications for Type 1 Cardiorenal Syndrome.Renin-angiotensin inhibition in systolic heart failure and chronic kidney diseaseNon-cardiac comorbidities in chronic heart failure.Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trialClinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.The association of chronic kidney disease with the use of renin-angiotensin system inhibitors after acute myocardial infarctionDrug insight: Immunomodulatory effects of statins--potential benefits for renal patients?Therapies for acute heart failure in patients with reduced kidney function: a community-based perspective.Primary and secondary prevention of heart failure with statins.Underutilization of evidence-based therapies in heart failure: the pharmacist's role.Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study.
P2860
Q22242077-C43F3546-0EB4-43D1-82E5-F1C3E65D1E77Q26797153-5BBDAA89-1D58-40FF-BEAC-BC6917DF6363Q26822738-701D523C-065A-4C25-A096-6DA8D590C046Q26824149-3984C573-956F-482A-BD4E-C5F6D68F9032Q26998966-69A65CAE-7B9A-40DB-AB1A-1BBCC2159A70Q27023089-F423C30C-63C3-4ED8-B880-1E2CAC575696Q28073813-5D64D540-3E2B-4546-A308-ABB1329E3271Q28195710-ED8E6B92-4289-45D8-BE19-9228474A4067Q28200294-D1B43FB8-4F59-475F-8246-0C8E0B1404FCQ28278243-F4BA1575-C2E5-4ECC-97B1-45B37CE013D6Q28550033-ABC5D921-4033-495B-86B6-2301F9A050B8Q30235107-410D7A51-EFD7-41E0-9C3F-73A57F79D8F9Q30235600-37EC0349-8D08-47A8-B777-14314ADDF26AQ30407860-71658091-85ED-4D1C-A83A-68B818FD3027Q33479788-5145DB2A-3DA7-456F-B08F-A8AB7EAFAD18Q33654021-C6F0B549-BF4A-4D9D-9712-275416D91E0AQ33711038-B8CE07FF-3C53-46B5-9946-7B7E0DC1AFEAQ33764626-194D163E-163B-4A40-9A09-E3BBAF1A7DA5Q33964843-F47284C3-2813-4DE9-91CB-390135248520Q33978466-436D875A-1781-4E0C-897A-A65FB8DA30BFQ34019491-A30ABEEB-8DA3-4D95-AF9C-A700A7A99BCAQ34020768-B9000AE6-02B4-4CF7-8718-4E78D9AFACFDQ34264037-B570F221-3369-4073-8992-140CB90728CDQ34322180-FE2EF753-D832-4CE3-9B96-9B4791C2D542Q34360297-91652270-70F1-4E32-9369-B88819842D3EQ34390665-1D54679A-093C-4EC4-93D0-5F836DC1B80EQ34985796-9EE9F020-10FB-412A-98AC-77B9BD054FEFQ35021961-3D48BE74-8226-4276-B176-243312FD9C81Q35043153-B904884D-6983-4D9D-A8D9-FB3CF31C846FQ35884936-B98818F9-9D5A-4A3C-BA1F-CF16CA4F9DB5Q35954727-359C3ECA-332E-4972-9D07-25029EF308FFQ36092082-61BE9986-3F4C-4FDF-8BA7-06A14BC0380FQ36441592-F27353E7-60D3-4A45-BDB7-A1C2418B326CQ36551356-35A45645-ABC7-45F3-9A48-2616678A16E7Q36557863-BBBE1987-62C9-449D-9A98-237A5EE2AD51Q36577189-2BF8CB8C-23B9-4D13-B721-2003392E598CQ36649708-21728B7E-A851-4118-9400-E052533AF13EQ36686069-440C8251-7A73-4CB6-B9B9-DC75D83C29A0Q36768252-B18E46A0-B826-4B6D-B0C1-360CF025CC5CQ37017442-45E25B73-057A-4691-B205-5C027774213B
P2860
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The association among renal in ...... re and coronary artery disease
@ast
The association among renal in ...... re and coronary artery disease
@en
The association among renal in ...... re and coronary artery disease
@nl
type
label
The association among renal in ...... re and coronary artery disease
@ast
The association among renal in ...... re and coronary artery disease
@en
The association among renal in ...... re and coronary artery disease
@nl
prefLabel
The association among renal in ...... re and coronary artery disease
@ast
The association among renal in ...... re and coronary artery disease
@en
The association among renal in ...... re and coronary artery disease
@nl
P2093
P50
P921
P1476
The association among renal in ...... re and coronary artery disease
@en
P2093
Finlay A McAlister
Karin H Humphries
Merril L Knudtson
William A Ghali
P304
P356
10.1016/J.JACC.2004.06.072
P407
P577
2004-10-19T00:00:00Z